Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › musculoskeletal diseases

Musculoskeletal diseases

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for musculoskeletal diseases

11 trials tracked for musculoskeletal diseases: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 455 citations.

11Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 2 Phase 1 1 Other / NA 5
  1. Phase 3 Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Completed · 455 cited
  2. Phase 3 A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia Completed
  3. Phase 3 A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee Completed
  4. Phase 2 A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Completed
  5. Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee Completed
  6. Phase 1 Phase 1 Study of ACE-083 in Healthy Subjects Completed
Show 5 more trials
  1. N/A Marathon and Enduron Polyethylene at Long-Term Follow-up Completed
  2. N/A Evaluation of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Revision Arthroplasty. Completed
  3. N/A Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty Completed
  4. N/A Medacta NextAR TKA Pivotal Trial Completed
  5. N/A A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Musculoskeletal diseases: what the trials found

In the management of fibromyalgia, TNX-102 SL Tablet (2.8mg) demonstrated improvements in both symptoms and function domains at week 12 as measured by the Fibromyalgia Impact Questionnaire - Revised (FIQR) 2.

For osteoarthritis patients treated with hylan G-F 20 over a 26-week period, significant reductions were observed in pain scores on the WOMAC LK 3.1 A (Pain) subscale 3. Additionally, participants reported significantly lower levels of pain while walking at week 26 compared to baseline 3.

Recent results — preliminary, needs further review

  • The NextAR TKA system was evaluated with results showing an Oxford Knee Score (OKS) of 41, Forgotten Joint Scores (FJS) between 56.2 and 60.4, and Objective Knee Society Scores (KSS) between 87.0 and 88.5 7.
  • LEVI-04 was evaluated in a Phase 2 trial 4.

For the clinician treating this condition

  • TNX-102 SL Tablet showed statistically significant improvements in fibromyalgia symptoms and function scores at 12 weeks 2.
  • Hylan G-F 20 is associated with a reduction in knee pain and walking pain for patients with osteoarthritis over a 26-week period 3.

AI synthesis of 4 cited trials, updated Jul 2, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.